Thrombosis News and Research

Latest Thrombosis News and Research

Age, gender and malignancies pose significant risk factors for TIVADs survival

It is common practice to insert totally implantable venous access devices (TIVADs) in cancer patients beginning a course of chemotherapy to eliminate potential peripheral venous access problems; however, risk factors impacting the survival of TIVADs remain unclear.

20 Oct 2009

Health Canada approves new Lantus ClikSTAR reusable insulin pen

Health Canada has approved the ClikSTAR reusable insulin pen for use with Lantus, giving patients with diabetes an additional option to safely and effectively achieve and sustain control of their blood sugar levels. The new insulin delivery device was launched today in conjunction with the 20th World Diabetes Congress being held in Montreal, Quebec, making Canada one of the first countries worldwide to launch this state-of-the-art pen.

20 Oct 2009

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

Schering-Plough announced that data on boceprevir, an investigational hepatitis C virus (HCV) protease inhibitor, will be reported in an oral presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston, Oct. 30-Nov. 3.

19 Oct 2009

New range of foods from marine animals and plants to help fight human diseases

Milk drinks that lower blood pressure, meat products that reduce the risk of heart disease, chocolate that calms you down and a new range of foods that can fight obesity can be created from marine animals and plants. Japan already has several product ranges on the shelves and research programmes are underway all over the world to create more.

15 Oct 2009

More than half RCTs do not report vital information about study populations race, says study

A new study recently published online by the American Heart Journal shows that more than half of all randomized clinical trials, or RCTs, for cardiovascular disease are not reporting vital information about the study populations race or ethnicity. NYU School of Medicine researchers found that out of the 156 cardiovascular disease RCTs analyzed, only 35% of trials reported any information on race or ethnicity between 1970 and 2006. From 2000 to 2006, 46% of trials included that information.

15 Oct 2009

European Patent Office to grant two intellectual property patents to Athera Biotechnologies

Athera Biotechnologies AB, an atherosclerosis R&D company developing novel products for treatment and prevention of cardiovascular disease (CVD), announced today that the European Patent Office intends to grant two key patents related to the Company's intellectual property on its two pharmaceutical candidates Annexin A5 and PC-mAb.

14 Oct 2009

Important issues facing nephrologists to be presented by Satellite Healthcare

Satellite Healthcare, one of the nation's first and leading providers of kidney dialysis services and a major sponsor of nephrology research, today announced that its chief researchers will present at The American Society of Nephrology (ASN) Renal Week 2009.

14 Oct 2009

New device minimizes brain damage by speeding the delivery of post-stroke countermeasures

A new device from NeuroInterventions, Inc., is designed to minimize brain damage by dramatically speeding the delivery of post-stroke countermeasures.

12 Oct 2009

The Quebec Biopharmaceutical Strategy lauded by Sanofi-aventis

Sanofi-aventis Canada welcomes the Quebec Biopharmaceutical Strategy and sees a strong link with its new corporate strategy.

9 Oct 2009

New cancer drugs boost drug spending

Cancer treatments are on track to become the biggest driver of specialty pharmacy spending as its contribution to overall drug spending hit five percent for the first time in the first half of 2009, according to Medco Health Solutions, Inc.

8 Oct 2009

Complications of otitis media: Evolving trends in children

The introduction of pneumococcal vaccines for treating otitis media in children has not prevented complications from occurring, according to new research presented at the 2009 American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting & OTO EXPO, in San Diego, CA. In fact, the research suggests that the focus has changed on what complications may arise.

8 Oct 2009

Global pharmaceutical market to grow by 4 - 6 percent: IMS Health

IMS Health reported today that the value of the global pharmaceutical market in 2010 is expected to grow 4 - 6 percent on a constant-dollar basis, exceeding $825 billion, driven by stronger near-term growth in the U.S. market.

8 Oct 2009

Schering-Plough receives FDA recommendation approval for PEGINTRON

Schering-Plough Corp. announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval by a vote of six to four for PEGINTRON® (pegylated interferon alfa-2b) in the adjuvant treatment of patients with Stage III malignant melanoma.

6 Oct 2009

HCRI commences patient enrollment in dual antiplatelet therapy study

The Harvard Clinical Research Institute (HCRI) announced today that the first patients have been enrolled in the DAPT Study, marking the official initiation of the four-year clinical trial to investigate the duration of dual antiplatelet therapy (DAPT, the combination of aspirin and a thienopyridine/antiplatelet medication to reduce the risk of blood clots) following drug-eluting stent implantations.

3 Oct 2009

CHI announces its speaker lineup for the 2009 California Healthcare Policy Forum

California Healthcare Institute today announced its speaker lineup for the 2009 California Healthcare Policy Forum to be held Nov. 5, at the InterContinental Mark Hopkins San Francisco Hotel, from 11:30 a.m. to 6:00 p.m.

3 Oct 2009

ACS NSQIP recognizes Baylor Dallas for achieving exemplary outcomes for surgical patient care

Baylor University Medical Center at Dallas has been recognized as one of 25 hospitals in the nation achieving exemplary outcomes for surgical patient care.

1 Oct 2009

HORIZONS-AMI clinical trial demonstrates efficacy of drug-eluting stent

Late-breaking data from the landmark HORIZONS-AMI clinical trial, presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, demonstrated that after two years, in heart attack patients, the use of a drug-eluting stent (paclitaxel) was safer and more effective than a bare-metal stent; and that the administration of the anticoagulant medication bivalirudin enhanced safety and efficacy compared to the use of heparin + GPIIb/IIIa inhibitors.

25 Sep 2009

Phase III PLATO study proves that ticagrelor is more effective than clopidogrel

New data from the phase III PLATO study showed that ticagrelor (BRILINTA((TM))) provided greater reduction of cardiovascular (CV) events (composite of CV death, heart attack and stroke) than clopidogrel (9.02% vs. 10.65%,>

25 Sep 2009

Cepheid receives approval to market Xpert(R) HemosIL(R) FII & FV test

Cepheid and Instrumentation Laboratory (IL) today announced that Cepheid has received clearance from the U.S. Food & Drug Administration (FDA) to market its Xpert(R) HemosIL(R) FII & FV test.

25 Sep 2009

Everolimus-eluting stent efficient in treating native coronary artery lesions

Late-breaking data from SPIRIT IV, a large-scale multi-center study of nearly 4,000 patients in the U.S., shows that an everolimus-eluting stent demonstrated enhanced safety and efficacy in the treatment of de novo native coronary artery lesions when compared to a paclitaxel-eluting stent, and showed that "low late loss" may be achieved with drug-eluting stents without sacrificing safety.

24 Sep 2009